Lisata Therapeutics Inc
LSTA2.550USD
+0.060+2.41%
收盤 08/04, 16:00（美東）報價延遲15分鐘
21.98M總市值
虧損本益比TTM
關於 Lisata Therapeutics Inc 公司
Lisata Therapeutics, Inc. 是一家臨牀階段製藥公司。該公司致力於發現、開發和商業化用於治療實體瘤和其他主要疾病的創新療法。其主要在研產品候選藥物 LSTA1 旨在激活一種新型攝取途徑，使共同給藥或連接的抗癌藥物能夠滲透到實體瘤中。LSTA1 以腫瘤特異性方式啓動這種主動運輸系統，導致系統性共同給藥的抗癌藥物滲透並積聚在腫瘤中，而正常組織不受影響。LSTA1 還具有改變腫瘤微環境 (TME) 的潛力。該公司正在探索 LSTA1 的潛力，以實現多種治療方式來治療一系列實體瘤。其 CD34+ 是一種細胞治療技術，針對一系列疾病，其中包括嚴重肢體缺血、冠狀動脈微血管功能障礙和糖尿病腎病。
公司簡介
公司代碼LSTA
公司名稱Lisata Therapeutics Inc
上市日期Nov 03, 1995
CEODr. David J. Mazzo, Ph.D.
員工數量26
證券類型Ordinary Share
年結日Nov 03
公司地址110 Allen Road
城市BASKING RIDGE
上市交易所NASDAQ Capital Market Consolidated
國家United States of America
郵編07920
電話19082292590
網址https://www.lisata.com/
公司代碼LSTA
上市日期Nov 03, 1995
CEODr. David J. Mazzo, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. David J. Mazzo, Ph.D.
Dr. David J. Mazzo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
264.69K
+3.26%
Dr. Kristen K. Buck, M.D.
Dr. Kristen K. Buck, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
79.79K
--
Dr. Mohammad Azab, M.D.
Dr. Mohammad Azab, M.D.
Independent Director
Independent Director
52.28K
+23.92%
Mr. Steven Mark (Steve) Klosk, J.D.
Mr. Steven Mark (Steve) Klosk, J.D.
Independent Director
Independent Director
49.57K
+8.05%
Dr. Gregory B. Brown, M.D.
Dr. Gregory B. Brown, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
49.41K
+8.07%
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
39.48K
+10.31%
Tariq Imam
Tariq Imam
Senior Vice President, Business Development and Operations and General Counsel
Senior Vice President, Business Development and Operations and General Counsel
24.58K
--
Mr. James Nisco
Mr. James Nisco
Senior Vice President - Finance and Treasury, Chief Accounting Officer
Senior Vice President - Finance and Treasury, Chief Accounting Officer
23.49K
--
Mr. John D. Menditto
Mr. John D. Menditto
Vice President - Investor Relations & Corporate Communications
Vice President - Investor Relations & Corporate Communications
--
--
Ms. Cynthia L. Flowers
Ms. Cynthia L. Flowers
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Dr. David J. Mazzo, Ph.D.
Dr. David J. Mazzo, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
264.69K
+3.26%
Dr. Kristen K. Buck, M.D.
Dr. Kristen K. Buck, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
79.79K
--
Dr. Mohammad Azab, M.D.
Dr. Mohammad Azab, M.D.
Independent Director
Independent Director
52.28K
+23.92%
Mr. Steven Mark (Steve) Klosk, J.D.
Mr. Steven Mark (Steve) Klosk, J.D.
Independent Director
Independent Director
49.57K
+8.05%
Dr. Gregory B. Brown, M.D.
Dr. Gregory B. Brown, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
49.41K
+8.07%
Ms. Heidi Henson, CPA
Ms. Heidi Henson, CPA
Independent Director
Independent Director
39.48K
+10.31%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月16日 週五
更新時間: 5月16日 週五
持股股東
股東類型
持股股東
持股股東
佔比
Ruoslahti (Erkki)
12.83%
Mazzo (David J)
3.08%
The Vanguard Group, Inc.
2.96%
BML Capital Management LLC
2.52%
Renaissance Technologies LLC
1.19%
Other
77.42%
持股股東
持股股東
佔比
Ruoslahti (Erkki)
12.83%
Mazzo (David J)
3.08%
The Vanguard Group, Inc.
2.96%
BML Capital Management LLC
2.52%
Renaissance Technologies LLC
1.19%
Other
77.42%
股東類型
持股股東
佔比
Individual Investor
20.18%
Investment Advisor/Hedge Fund
4.24%
Investment Advisor
3.51%
Hedge Fund
1.22%
Research Firm
0.14%
Other
70.70%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
48
2.52M
29.30%
-63.24K
2025Q1
50
2.57M
30.49%
+155.41K
2024Q4
48
2.39M
27.90%
-46.00K
2024Q3
48
2.33M
27.50%
-84.74K
2024Q2
59
2.31M
27.35%
-158.27K
2024Q1
60
2.32M
28.57%
+1.21M
2023Q4
63
2.13M
26.53%
+1.00M
2023Q3
72
2.18M
28.45%
+396.20K
2023Q2
72
2.18M
28.62%
+428.28K
2023Q1
74
1.03M
14.30%
-575.31K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Ruoslahti (Erkki)
1.10M
12.83%
-78.14K
-6.62%
Apr 17, 2025
Mazzo (David J)
264.69K
3.08%
+8.35K
+3.26%
Apr 17, 2025
The Vanguard Group, Inc.
254.18K
2.96%
+67.82K
+36.39%
Mar 31, 2025
BML Capital Management LLC
216.85K
2.52%
-67.82K
-23.82%
Mar 31, 2025
Renaissance Technologies LLC
102.72K
1.19%
+1.40K
+1.38%
Mar 31, 2025
Buck (Kristen K)
79.79K
0.93%
--
--
Apr 17, 2025
Geode Capital Management, L.L.C.
60.53K
0.7%
+4.63K
+8.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
54.86K
0.64%
-1.16K
-2.06%
Mar 31, 2025
Azab (Mohammad)
52.28K
0.61%
+10.09K
+23.92%
Apr 17, 2025
Klosk (Steven Mark)
49.57K
0.58%
+3.69K
+8.05%
Apr 17, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
iShares Core S&P Total U.S. Stock Market ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
佔比0%
DFA Dimensional US Sustainability Core 1 ETF
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Sep 14, 2022
Merger
15<1
Sep 14, 2022
Merger
15<1
Sep 14, 2022
Merger
15<1
Sep 14, 2022
Merger
15<1
公告日期
類型
比率
Sep 14, 2022
Merger
15<1
Sep 14, 2022
Merger
15<1
Sep 14, 2022
Merger
15<1
Sep 14, 2022
Merger
15<1
